Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects

Next Previous
X
Search
Trial Profile

Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostemsavir (Primary) ; Darunavir/ritonavir; Etravirine
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 22 Mar 2022 Results assessing drug-drug interactions (DDIs) in two open-label, single-sequence, multiple-dose studies (NCT02063360 and NCT02277600) published in the Antimicrobial Agents and Chemotherapy.
    • 25 Feb 2015 Results published in a Bristol-Myers Squibb media release and presented at the 22nd Conference on Retroviruses and Opportunistic Infections.
    • 14 Aug 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top